Journal of Clinical Endocrinology & Metabolism, Vol 79, 1831-1834, Copyright © 1994 by Endocrine Society

ARTICLES

CYP19 (aromatase cytochrome P450) gene expression in human malignant endometrial tumors

SE Bulun, K Economos, D Miller and ER Simpson
Cecil H. and Ida Green Center for Reproductive Biology Sciences, Univeristy of Texas Southwestern Medical Center, Dallas 75235.

C19 steroids are converted to estrogens in a number of human tissues by the aromatase enzyme complex, which consists of aromatase cytochrome P450 (P450arom; product of the CYP19 gene) and NADPH-cytochrome P450 reductase. Aromatase activity has been previously demonstrated in endometrial tumors. In the present study, we investigated CYP19 gene expression and its regulation in endometrial tumor samples (n = 9). Using a specific method of competitive polymerase chain reaction after reverse transcription, varying levels of P450arom transcripts were detected in all endometrial adenocarcinomas (n = 8) and one mixed Mullerian tumor studied. No correlations were observed between P450arom transcript levels and histological type of the tumor, grade, myometrial invasion, stage of the disease, or patient age. We have recently demonstrated that the tissue-specific regulation of CYP19 gene transcription is in part the consequence of alternative promoter use. The use of each promoter gives rise to a P450arom transcript with a unique untranslated 5'-end. We analyzed the untranslated first exons in 5'-terminals of P450arom transcripts in endometrial adenocarcinomas using a specific reverse transcription-polymerase chain reaction/Southern hybridization method we recently developed. Our findings indicated the gonadal-type (promoter II) and one of the adipose stromal cell-type (I.3) promoters were primarily used for P450arom expression in adenocarcinomas. On the other hand, distribution of transcripts specific for I.3, I.4 (another adipose-type promoter), and promoter II in one mixed Mullerian tumor was uniform. Placental promoter (I.1)-specific P450arom transcripts were not detected in endometrial tumors. As P450arom transcripts were detected in all endometrial malignancies studied, whereas they were not demonstrable in the disease-free endometrium, activation or failure of inhibition of aromatase expression in these tumors may serve to promote neoplastic proliferation.

This article has been cited by other articles:

				M. Matsumoto, Y. Yamaguchi, Y. Seino, A. Hatakeyama, H. Takei, H. Niikura, K. Ito, T. Suzuki, H. Sasano, N. Yaegashi, et al. Estrogen signaling ability in human endometrial cancer through the cancer-stromal interaction Endocr. Relat. Cancer, June 1, 2008; 15(2): 451 - 463. [Abstract] [Full Text] [PDF]

				S. D. MacLaughlan, W. A. Palomino, B. Mo, T. D. Lewis, R. A. Lininger, and B. A. Lessey Endometrial Expression of Cyr61: A Marker of Estrogenic Activity in Normal and Abnormal Endometrium Obstet. Gynecol., July 1, 2007; 110(1): 146 - 154. [Abstract] [Full Text] [PDF]

				M. H. Tao, Q. Cai, Z.-F. Zhang, W.-H. Xu, N. Kataoka, W. Wen, Y.-B. Xiang, W. Zheng, and X. O. Shu Polymorphisms in the CYP19A1 (Aromatase) Gene and Endometrial Cancer Risk in Chinese Women Cancer Epidemiol. Biomarkers Prev., May 1, 2007; 16(5): 943 - 949. [Abstract] [Full Text] [PDF]

				S. H. Olson, E. V. Bandera, and I. Orlow Variants in Estrogen Biosynthesis Genes, Sex Steroid Hormone Levels, and Endometrial Cancer: A HuGE Review Am. J. Epidemiol., February 1, 2007; 165(3): 235 - 245. [Abstract] [Full Text] [PDF]

				J. T. Sanderson The Steroid Hormone Biosynthesis Pathway as a Target for Endocrine-Disrupting Chemicals Toxicol. Sci., November 1, 2006; 94(1): 3 - 21. [Abstract] [Full Text] [PDF]

				S. E. Bulun, Z. Lin, G. Imir, S. Amin, M. Demura, B. Yilmaz, R. Martin, H. Utsunomiya, S. Thung, B. Gurates, et al. Regulation of Aromatase Expression in Estrogen-Responsive Breast and Uterine Disease: From Bench to Treatment Pharmacol. Rev., September 1, 2005; 57(3): 359 - 383. [Abstract] [Full Text] [PDF]

				T. Segawa, M. Shozu, K. Murakami, T. Kasai, K. Shinohara, K. Nomura, S. Ohno, and M. Inoue Aromatase Expression in Stromal Cells of Endometrioid Endometrial Cancer Correlates with Poor Survival Clin. Cancer Res., March 15, 2005; 11(6): 2188 - 2194. [Abstract] [Full Text] [PDF]

				T. Nakanishi, J. Kohroki, S. Suzuki, J. Ishizaki, Y. Hiromori, S. Takasuga, N. Itoh, Y. Watanabe, N. Utoguchi, and K. Tanaka Trialkyltin Compounds Enhance Human CG Secretion and Aromatase Activity in Human Placental Choriocarcinoma Cells J. Clin. Endocrinol. Metab., June 1, 2002; 87(6): 2830 - 2837. [Abstract] [Full Text] [PDF]

				A. Zeitvogel, R. Baumann, and A. Starzinski-Powitz Identification of an Invasive, N-Cadherin-Expressing Epithelial Cell Type in Endometriosis Using a New Cell Culture Model Am. J. Pathol., November 1, 2001; 159(5): 1839 - 1852. [Abstract] [Full Text] [PDF]

				H. Sumitani, M. Shozu, T. Segawa, K. Murakami, H.-J. Yang, K. Shimada, and M. Inoue In Situ Estrogen Synthesized by Aromatase P450 in Uterine Leiomyoma Cells Promotes Cell Growth Probably Via an Autocrine/Intracrine Mechanism Endocrinology, October 1, 2000; 141(10): 3852 - 3861. [Abstract] [Full Text] [PDF]

				J. T. Sanderson, W. Seinen, J. P. Giesy, and M. van den Berg 2-Chloro-s-Triazine Herbicides Induce Aromatase (CYP19) Activity in H295R Human Adrenocortical Carcinoma Cells: A Novel Mechanism for Estrogenicity? Toxicol. Sci., March 1, 2000; 54(1): 121 - 127. [Abstract] [Full Text] [PDF]

				H. Sasano and N. Harada Intratumoral Aromatase in Human Breast, Endometrial, and Ovarian Malignancies Endocr. Rev., October 1, 1998; 19(5): 593 - 607. [Abstract] [Full Text]

				L. Dalla Valle, A. Ramina, S. Vianello, A. Fassina, P. Belvedere, and L. Colombo Potential for Estrogen Synthesis and Action in Human Normal and Neoplastic Thyroid Tissues J. Clin. Endocrinol. Metab., October 1, 1998; 83(10): 3702 - 3709. [Abstract] [Full Text]

				V. R. Agarwal, K. Takayama, J. J. Van Wyk, H. Sasano, E. R. Simpson, and S. E. Bulun Molecular Basis of Severe Gynecomastia Associated with Aromatase Expression in a Fibrolamellar Hepatocellular Carcinoma J. Clin. Endocrinol. Metab., May 1, 1998; 83(5): 1797 - 1800. [Abstract] [Full Text]

				C. A. Stratakis, A. Vottero, A. Brodie, L. S. Kirschner, D. DeAtkine, Q. Lu, W. Yue, C. S. Mitsiades, A. W. Flor, and G. P. Chrousos The Aromatase Excess Syndrome Is Associated with Feminization of Both Sexes and Autosomal Dominant Transmission of Aberrant P450 Aromatase Gene Transcription J. Clin. Endocrinol. Metab., April 1, 1998; 83(4): 1348 - 1357. [Abstract] [Full Text]

				M. Shozu, Y. Zhao, S. E. Bulun, and E. R. Simpson Multiple Splicing Events Involved in Regulation of Human Aromatase Expression by a Novel Promoter, I.6 Endocrinology, April 1, 1998; 139(4): 1610 - 1617. [Abstract] [Full Text] [PDF]

				L. S. Noble, K. Takayama, K. M. Zeitoun, J. M. Putman, D. A. Johns, M. M. Hinshelwood, V. R. Agarwal, Y. Zhao, B. R. Carr, and S. E. Bulun Prostaglandin E2 Stimulates Aromatase Expression in Endometriosis-Derived Stromal Cells J. Clin. Endocrinol. Metab., February 1, 1997; 82(2): 600 - 606. [Abstract] [Full Text] [PDF]